Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

18 results about "Reticulocyte" patented technology

Reticulocytes are immature red blood cells (RBCs). In the process of erythropoiesis (red blood cell formation), reticulocytes develop and mature in the bone marrow and then circulate for about a day in the blood stream before developing into mature red blood cells. Like mature red blood cells, in mammals, reticulocytes do not have a cell nucleus. They are called reticulocytes because of a reticular (mesh-like) network of ribosomal RNA that becomes visible under a microscope with certain stains such as new methylene blue and Romanowsky stain.

Reticulocyte recognition and grading system based on blood smear

The invention discloses a reticulocyte recognition and grading system based on a blood smear, and particularly relates to the field of medical cell morphology examination, and the system comprises an image acquisition module, a staining normalization module, an instance segmentation module, an erythrocyte classification module, a reticulocyte grading module and a statistics output module. The image acquisition module adopts an automatic microscope platform to continuously scan the blood smear under a 100-time visual field, acquires a high-quality bright field channel image through an automatic focusing technology, and monitors image definition, contrast and illumination uniformity; the statistical output module is used for calculating the proportion and bluish violet intensity statistics of reticulocytes of each level, and generating a visual quality control result and a diagnostic report; according to the invention, full-automatic processing from samples to reports is realized, interpretability and high classification precision are both considered, subjective difference and omission ratio of manual microscopic examination are significantly reduced, and efficiency and consistency of clinical detection are improved.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Image processing method and device for judging hemolysis of suspended red blood cells

ActiveCN121708635ABiological modelsAcquiring/recognising microscopic objectsCoboglobinBlood parameters
The invention discloses an image processing method and device for judging suspension red blood cell hemolysis. The method comprises the following steps: acquiring a blood image set; the blood image set comprises a plurality of blood images and corresponding label information; acquiring a blood parameter information set; the blood parameter information set comprises a plurality of blood parameters and corresponding label information; the blood parameters comprise hemoglobin concentration, reticulocyte concentration, indirect bilirubin concentration, lactic dehydrogenase concentration and globin concentration; utilizing the blood image set and the blood parameter information set to construct a blood hemolysis composite detection model; based on the blood hemolysis composite detection model, processing the collected blood image and blood parameters to obtain hemolysis detection result information; the hemolysis detection result information is used for representing erythrocyte hemolysis information of the blood corresponding to the collected blood image and blood parameters.
Owner:THE SIXTH MEDICAL CENT OF THE CHINESE PEOPLES LIBERATION ARMY GENERAL HOSPITAL

Reticulocyte staining method

A method for staining reticulocytes includes staining reagent A and stabilizing reagent B; stabilizing reagent B is used M seconds after staining reagent A is mixed with the sample; M is greater than or equal to 20 seconds; staining reagent A includes staining agent A10, adjusting salt C10, and water; staining agent A10 is neomethylene blue; the concentration of neomethylene blue in staining reagent A is 0.8 × 10⁻⁶. ‑4 g / ml ~ 8.0 × 10 ‑4 g / mL; adjusting salt C10 is used to provide a low osmotic pressure environment and a pH range of 7.0–8.0; stabilizing reagent B includes staining stabilizer B10, adjusting salt D10, and water; the staining stabilizer B10 in stabilizing reagent B includes aldehydes. A unique two-step reagent formulation and method are used to achieve rapid staining of reticulocytes in a step-by-step manner, achieving successful staining in just 20 seconds, and the staining effect can be maintained for a sufficiently long time, exceeding 120 minutes.
Owner:SHENZHEN ANLV MEDICAL TECH CO LTD

Method for preparing reticulocyte simulating particles and platelet simulating particles, and reference control

Provided are a method for preparing reticulocyte simulating particles and platelet simulating particles, and a reference control. The method for preparing the reticulocyte simulating particles comprises: staining mammalian anucleated red blood cells having a volume of 60-120 fL with a protein fluorescent dye activated by N-hydroxysuccinimide, and fixing the anucleated red blood cells to prepare the reticulocyte simulating particles. The platelet simulating particles are prepared from mammalian anucleated red blood cells having a volume of 2-25 fL, and the steps of preparing the platelet simulating particles are the same as that for the reticulocyte simulating particles. The preparation method comprises: using an protein fluorescent dye activated by N-hydroxysuccinimide to stain mammalian anucleated red blood cells having different volumes, so as to respectively obtain reticulocyte simulating particles and platelet simulating particles.
Owner:SHENZHEN MINDRAY BIO MEDICAL ELECTRONICS CO LTD

Stabilised protein

The present disclosure relates to synthetic Plasmodium reticulocyte binding protein 2b (mRBP2b) antigens that have improved properties such as thermal stability, as well as the use of these antigens to detect a Plasmodium infection in a diagnostic device or for use in a vaccine.
Owner:THE WALTER AND ELIZA HALL INSTITUTE OF MEDECAL RESEARCH +1

Application of qi-tonifying and blood-nourishing preparation in preparation of medicine for treating thalassemia

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to application of a qi-tonifying and blood-maintaining preparation in preparation of a medicine for treating thalassemia. Researches show that the preparation for tonifying qi and maintaining blood is used for treating thalassemia and can effectively improve the anemia state and iron metabolism disorder of patients. Specifically, the medicine can significantly improve the hemoglobin level, increase the red blood cell count and the red blood cell average volume, and improve the serum iron content, the ferritin content and the reticulocyte proportion. The results show that the qi-tonifying and blood-maintaining preparation has the effect of promoting the bone marrow hematopoiesis function and can regulate and optimize the iron metabolism process. The invention provides an economical, effective and convenient treatment scheme for the thalassemia patient.
Owner:GUANGDONG HONGSHANHU PHARM CO LTD

Using an optical microscope to perform maturity classification of stained reticulocytes

The present invention relates to the use of light microscopy for reticulocyte maturity classification of stained reticulocytes. In particular, the present invention relates to a method for reticulocyte maturity classification from a whole blood sample, comprising: staining the sample with a supravital agglutination stain reagent or a fluorescent agglutination dye; illuminating the stained sample with a light beam to detect reticulocytes; determining for each reticulocyte the parameters (i) the fraction of reticular area (Ar) relative to the whole cell area (Ac) (Λ) and (ii) the fraction of reticular perimeter (Ur) relative to the reticular area (Ar) (Γ); and classifying the reticulocyte maturity into one of four main maturity classes according to the determined Λ and Γ values.
Owner:SIEMENS HEALTHCARE DIAGNOSTICS INC

A reticulocyte identification and grading system based on blood smears

ActiveCN121354096BContinuous scanningStaining
The application discloses a reticulocyte identification and grading system based on blood smears, and particularly relates to the field of medical cell morphology inspection, and comprises an image acquisition module, a staining normalization module, an instance segmentation module, an erythrocyte classification module, a reticulocyte grading module and a statistical output module; the image acquisition module: adopts an automatic microscope platform to continuously scan blood smears under a 100-fold field of view, collects high-quality bright field channel images through automatic focusing technology, and monitors image definition, contrast and illumination uniformity; the statistical output module: calculates the proportion of reticulocytes at all levels and blue-purple intensity statistics, and generates visual quality control results and diagnosis reports; the application realizes full-automatic processing from samples to reports, takes into account interpretability and high classification accuracy, significantly reduces subjective differences and missed detection rates of manual microscopy, and improves the efficiency and consistency of clinical detection.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Blood cell analyzer and blood cell analysis method

The invention relates to a blood cell analyzer and a blood cell analysis method. The method comprises the following steps: mixing a part of a sucked blood sample to be detected, a diluent and a fluorescent staining agent in a first reaction tank to prepare a first determination sample, and obtaining first optical information generated after particles in the first determination sample are irradiated by light; mixing the other part of the blood sample to be detected with a hemolytic agent in a second reaction tank to prepare a second determination sample, and obtaining colorimetric optical information of the second determination sample; obtaining a reticulocyte detection result, a platelet detection result, an erythrocyte detection result and a first leukocyte detection result of the to-be-detected blood sample based on the first optical information, wherein the first leukocyte detection result at least comprises a lymphocyte percentage, a mononuclear cell percentage and a granulocyte percentage; and determining the hemoglobin concentration of the to-be-detected blood sample based on the colorimetric method optical information. According to the application, the reagent cost required for obtaining the detection result of the to-be-detected blood sample can be reduced.
Owner:SHENZHEN MINDRAY ANIMAL MEDICAL TECH CO LTD

Preparation method of polyethylene glycol amphotericin B micelle

The invention provides a preparation method of polyethylene glycol amphotericin B micelles, and belongs to the field of biological medicine manufacturing. The method comprises the following steps: reacting methoxy polyethylene glycol with lactide at 110-130 DEG C for 6-12 hours to obtain a block copolymer; the segmented copolymer and 2-(diisopropylamino) ethylamine are subjected to a reaction for 12-24 h, and a terpolymer is obtained; the terpolymer and 4-(hydroxymethyl) phenylboronic acid pinacol ester are subjected to a reaction for 12-36 h, and a quadripolymer is obtained; co-loading the quadripolymer and amphotericin B to obtain a micelle core; extracting a denucleated reticulated erythrocyte membrane from whole blood; and wrapping the outer surface of the micelle core with the denucleated reticulated erythrocyte membrane to obtain the polyethylene glycol amphotericin B micelle. Through the step-by-step design of intelligent response drug loading and bionic delivery camouflage, the dual purposes of'curative effect improvement and toxicity reduction 'of amphotericin B are achieved from three dimensions of accurate drug release, effective focus enrichment and normal tissue protection.
Owner:HANZHONG CENT HOSPITAL

Measurement method, measurement system, and test reagent kit

PendingUS20260185923A1StainingBlood specimen
A method, just requiring simple pretreatment, of concentration measurement for reticulocytes or nucleated erythrocytes includes a staining step, a removal step, and a measurement step. In the staining step, reticulocytes or nucleated erythrocytes among red blood cells contained in a blood specimen are stained. In the removal step, the blood specimen is mixed with a surfactant to extract hemoglobin from the red blood cells. In the measurement step, using the blood specimen having undergone the staining step and the removal step, the concentration of the reticulocytes or nucleated erythrocytes contained in the blood specimen is measured.
Owner:HORIBA LTD +1

Products and methods for treatment

PendingJP2026086602APeptide/protein ingredientsMuscular disorderErythrocyte precursorProtein target
The present invention provides a method for producing reticulocytes containing increased levels of target protein or polypeptide. [Solution] The method comprises (a) preparing a erythrocyte precursor capable of expressing the target protein or polypeptide, (b) expressing the target protein or polypeptide, and (c) maturing the erythrocyte precursor into a reticulocyte, wherein the target protein or polypeptide is configured and / or inhibited so as to interfere with or prevent ubiquitination of the target protein or polypeptide when the erythrocyte precursor is matured into a reticulocyte. Erythrocytes, pharmaceutical compositions and related methods of use, as well as a method for screening proteins or polypeptides that are degraded by ubiquitination during the maturation of erythrocyte precursors, are also provided.
Owner:UNIV OF BRISTOL

Image processing method and device for judging hemolysis of suspended red blood cells

ActiveCN121708635BRealize synergistic integrationincrease diversityCoboglobinBlood parameters
The application discloses an image processing method and device for judging hemolysis of suspended red blood cells, and the method comprises the following steps: acquiring a blood image set; the blood image set comprises a plurality of blood images and corresponding label information; acquiring a blood parameter information set; the blood parameter information set comprises a plurality of blood parameters and corresponding label information; the blood parameters comprise hemoglobin concentration, reticulocyte concentration, indirect bilirubin concentration, lactate dehydrogenase concentration and globin concentration; a blood hemolysis composite detection model is constructed by using the blood image set and the blood parameter information set; the collected blood image and blood parameter are processed based on the blood hemolysis composite detection model, and hemolysis detection result information is obtained; the hemolysis detection result information is used for representing the red blood cell hemolysis information of the corresponding blood of the collected blood image and blood parameter.
Owner:THE SIXTH MEDICAL CENT OF THE CHINESE PEOPLES LIBERATION ARMY GENERAL HOSPITAL

Transferrin receptor binding polypeptides and uses thereof

PendingJP2026010691AHybrid immunoglobulinsNervous disorderDimerNumber reticulocytes
To provide a means for delivering to the brain an effector function positive therapeutic agent that does not cause reticulocyte loss.SOLUTION: The present disclosure generally provides an Fc polypeptide dimer comprising a non-native transferrin receptor (TfR) binding site, wherein the Fc polypeptide dimer does not substantially deplete reticulocytes in vivo, but retains binding to an Fey receptor (FcyR). The present disclosure also provides an Fc polypeptide dimer wherein one of the Fc polypeptides comprises a non-native site that specifically binds TfR and a modification (s) in the Fc polypeptide comprising the TfR binding site that reduces binding of an Fc γ R when bound to TfR, wherein the other Fc polypeptide does not comprise a TfR binding site but retains binding to an Fc γ R.SELECTED DRAWING: None
Owner:DENALI THERAPEUTICS INC

Anti-HER2 polypeptides and methods of use thereof

This provides a novel therapeutic agent that can target HER2 in the brain parenchyma, transcending the blood-brain barrier (BBB). [Solution] In some embodiments, anti-HER2 constructs (e.g., Fc polypeptide dimer-antibody variable region fusion proteins) retain effector function upon binding to HER2 but do not substantially reduce reticulocytes in vivo. The disclosure also relates to methods for transcytosis of anti-HER2 antibody variable regions across the blood-brain barrier to treat HER2-positive cancers and their metastatic lesions.
Owner:DENALI THERAPEUTICS INC

Transdifferentiation immune function of nucleated red blood cells of ARDS patient and application thereof

PendingCN121385297AMicrobiological testing/measurementBiological testingTransdifferentiationErythrocyte differentiation
The invention discloses a transdifferentiation immunologic function of nucleated red blood cells of an ARDS patient and application of the transdifferentiation immunologic function, and belongs to the field of biomedicine. The first aspect of the invention relates to application of a reagent for detecting reticulocyte damage and / or a reagent for detecting T cell markers carried by nucleated red blood cells in preparation of a kit for diagnosing acute respiratory distress syndrome. On the second aspect, the invention relates to a method for detecting differentiation of nucleated red blood cells, which comprises the following steps: screening nucleated red blood cells which grow later; and detecting and / or counting nucleated red blood cells with T cell markers in nucleated red blood cells with later development. The invention discloses the differentiation phenomenon of nucleated red blood cells, and the nucleated red blood cells can be applied to the research of the ARDS process and the diagnosis of ARDS.
Owner:SOUTHEAST UNIV +1

Blood testing method and blood analysis system

A blood testing method and a corresponding blood analysis system, the method comprising: treating a blood sample with a first reagent containing a hemolytic agent to obtain a test sample (S11), wherein the hemolytic agent lyses red blood cells in the blood sample into fragments; obtaining optical information of the test sample by an optical detection device (50, 200) (S12), wherein particles in the test sample are passed one by one through a detection zone of the optical detection device (50, 200) and the particles in the test sample are illuminated with a light source (101) of the optical detection device (50, 200) to obtain the optical information of the test sample, wherein the light source (101) is configured to emit light with a wavelength of less than 488 nm; and obtaining optical information of platelets (S13) and / or optical information of reticulocytes from at least two of the optical information, wherein the optical information of the platelets and / or the reticulocytes is obtained in a detection channel in which the red blood cells in the blood sample are lysed.
Owner:SHENZHEN MINDRAY BIO MEDICAL ELECTRONICS CO LTD